Amyloid-Beta Treatment Impact: Limited Clinical...

By HEOR Staff Writer

April 17, 2026

Amyloid-Beta Treatment Impact on people with early Alzheimer’s disease is minimal, according to a major new Cochrane review. The analysis of 17 randomized controlled trials involving more than 20,000 participants found that amyloid-beta-targeting ...
Advancing B7-H3 Targeted Therapy for Relapsed Extensive-Stage Small Cell Lung...
Differentiated Visceral Fat Reduction in Early Trials of WVE-007
European Immunotherapy Approval for Ovarian Cancer: KEYTRUDA’s New Role...
Advancements in Immunotherapy for Hepatocellular Carcinoma: EMERALD-3 Trial R...
Nonclinical Safety Testing with Virtual Control Groups
Tarlatamab for Small Cell Lung Cancer Treatment
FDA Approves Once-Weekly Basal Insulin Awiqli® for Type 2 Diabetes Management
Inflation Reduction Act Impact on Clinical Trial Investment Trends
EU Alzheimer Approval Challenges: Anavex Withdraws Blarcamesine Application A...
Novartis Acquires Mutant-Selective PI3Kα Inhibitor to Enhance Breast Cancer T...
Wegovy HD Approval: A Game Changer in Obesity Treatment and Weight Loss Efficacy
Milestone Approval of Invasive Brain-Computer Interface Revolutionizes Spinal...